Amneal Pharmaceuticals (AMRX) Competitors

Amneal Pharmaceuticals (NASDAQ:AMRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Is AMRX or BPMC more profitable?

Amneal Pharmaceuticals has a net margin of -0.46% compared to Blueprint Medicines' net margin of -27.70%. Blueprint Medicines' return on equity of -64.60% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	-0.46%	-188.26%	5.34%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Does the MarketBeat Community prefer AMRX or BPMC?

Blueprint Medicines received 533 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.45% of users gave Amneal Pharmaceuticals an outperform vote while only 66.91% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Amneal Pharmaceuticals	Outperform Votes 21 95.45%	Underperform Votes 1 4.55%
Blueprint Medicines	Outperform Votes 554 66.91%	Underperform Votes 274 33.09%

Which has better valuation & earnings, AMRX or BPMC?

Blueprint Medicines has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$2.79B	0.91	-$116.89M	-$0.04	-203.25
Blueprint Medicines	$508.82M	16.28	-$67.09M	-$2.47	-51.93

Does the media favor AMRX or BPMC?

In the previous week, Blueprint Medicines had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Blueprint Medicines and 0 mentions for Amneal Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.32 beat Amneal Pharmaceuticals' score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Blueprint Medicines	Neutral

Which has more volatility & risk, AMRX or BPMC?

Amneal Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Do analysts prefer AMRX or BPMC?

Amneal Pharmaceuticals currently has a consensus price target of $11.60, indicating a potential upside of 42.68%. Blueprint Medicines has a consensus price target of $128.06, indicating a potential downside of 0.16%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Amneal Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.27

Do insiders & institutionals believe in AMRX or BPMC?

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.5% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks.